GlassScriptPhysician profile
Michael W Lenihan
NPI 1285727792
$64,829.48
in general payments reported to CMS, 2019-2025
41 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $753 · 2020: $8,583 · 2021: $12K · 2022: $5,932 · 2023: $3,513 · 2024: $20K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $7,840 · Food and Beverage: $5,578 · Travel and Lodging: $3,828 · Education: $38.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,393.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $7,840.00 |
| Food and Beverage | $5,577.54 |
| Travel and Lodging | $3,828.09 |
| Education | $38.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $19,632.45 | 2023-2025 | |
| Argenx US, INC. | $10,092.88 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Biohaven Pharmaceuticals, INC. | $9,901.82 | 2021 | |
| Allergan, INC. | $8,209.71 | 2019-2022 | |
| Ucb, INC. | $3,626.76 | 2019-2025 | Rystiggo, Zilbrysq |
| Livanova USA, INC. | $2,784.35 | 2022-2023 | Vns Therapy |
| Janssen Biotech, INC. | $2,225.30 | 2025 | |
| Abbvie INC. | $1,318.38 | 2021-2025 | |
| Genzyme Corporation | $958.87 | 2019-2025 | |
| Emd Serono, INC. | $930.59 | 2019-2025 | Mavenclad, Mavenclad |
| Banner Life Sciences, LLC | $900.00 | 2021 | |
| Neurelis, INC. | $466.82 | 2020-2025 | Valtoco |
| Biogen, INC. | $441.69 | 2019-2025 | Vumerity, Tysabri |
| Genentech USA, INC. | $413.27 | 2019-2025 | Ocrevus, Enspryng |
| Novartis Pharmaceuticals Corporation | $387.66 | 2019-2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lenihan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.